Literature DB >> 71013

The autoimmune features of acute transverse myelopathy.

O Abramsky, D Teitelbaum.   

Abstract

Lymphocytes from patients with acute transverse myelopathy (ATM) were shown to undergo a specific and significant transformation when cultured in vitro in the presence of either the central nervous myelin basic encephalitogenic protein (BE) or the peripheral nerve myelin P2 protein. A similar pattern of response was demonstrated in acute disseminated encephalomyelitis and in acute myeloradiculitis. Lymphocytes from patients suffering from other autoimmune neurological disorders or other neurological diseases affecting the spinal cord showed no response to there immunologically related antigens, which have previously been found to have the capacity of inducing experimental allergic encephalomyelitis, either alone or with experimental allergic neuritis, when injected into animals. The specific in vitro response to BE and P2 suggests that in vivo sensitization of lymphocytes to such self-antigens occurs in ATM and than a cell-mediated, probably postinfecious autoimmune mechanism may be an important factor in the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 71013     DOI: 10.1002/ana.410020106

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  3 in total

1.  High dose methylprednisolone in severe acute transverse myelopathy.

Authors:  G Sébire; H Hollenberg; L Meyer; G Huault; P Landrieu; M Tardieu
Journal:  Arch Dis Child       Date:  1997-02       Impact factor: 3.791

2.  Acute transverse myelitis caused by ECHO virus type 18 infection.

Authors:  S Takahashi; A Miyamoto; J Oki; H Azuma; A Okuno
Journal:  Eur J Pediatr       Date:  1995-05       Impact factor: 3.183

3.  Demyelinating optic neuropathy with Miller-Fisher syndrome. The case for overlap syndromes with central and peripheral demyelination.

Authors:  P Toshniwal
Journal:  J Neurol       Date:  1987-06       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.